Objective We sought to review evidence linking nuclear factor-kappa B (NF-jB) to ovarian cancer and to identify genetic variants involved in NF-jB signaling. Methods PubMed was reviewed to inform on ovarian cancer biology and NF-jB signaling and to identify key genes. Public linkage disequilibrium (LD) data were analyzed to identify informative inherited variants (tagSNPs) using ldSelect. Results We identified 319 key NF-jB genes including five NF-jB subunits, 167 activating genes, and 55 inhibiting genes. We found that the 1000 Genomes Project was the most informative LD source for most genes (92.8%), and we identified 13,027 LD bins (r 2 C 0.9, minor allele frequency C0.05) and 1,018 putative-functional variants worthy of investigation. We also report that reliance on a commonly used genome-wide SNP array and genotype imputation with HapMap Phase II data provides data on only 74% of the common inherited NF-jB SNPs of interest.
Introduction
Ovarian cancer is the fifth leading cause for cancer death among women in the United States [1] . Due to a lack of effective screening strategies and the non-specific nature of early signs and symptoms associated with this disease, most patients are diagnosed with advanced disease. For the approximate 25% of women who are diagnosed with disease confined to the ovary or ovaries, 5-year survival rates are high (75-90%); however, for the 75% of women diagnosed with stage III and IV disease, the likelihood of long-term disease-free survival is low (15-20%) [2] [3] [4] . Identification of factors associated with risk and clinical outcome is essential to understand the pathogenesis of ovarian cancer, enabling preventative and therapeutic advances to be made in this rare but deadly disease.
Recent studies indicate that there are two distinct types of ovarian cancer, Type I and Type II [5] , and that a proportion of cases of both types likely originate in pelvic tissues outside the ovary. Ovarian cancer is originally thought to develop de novo from the ovarian surface epithelium that is derived from mesodermal epithelium and contains no müllerian-type tissue. However, serous, endometrioid, and clear cell ovarian carcinomas are all derived from müllerian-type tissue indicating that ovarian tumors may not develop de novo in the ovary, but instead develop in müllerian-derived tissues outside ovary (such as the cervix, endometrium, and fallopian tubes) and involve the ovary secondarily [6] [7] [8] . Type I ovarian cancers (clear cell, mucinous carcinomas, and low-grade serous and endometrioid) are usually confined to the ovaries at diagnosis, develop from borderline tumor precursors, and are relatively genetically stable with typical somatic mutations, including KRAS, BRAF, ERBB2, and PIK3CA but not TP53 [9] . Type II ovarian cancers (high-grade serous, high-grade endometrioid, malignant mixed mesodermal tumors, and undifferentiated carcinomas) are more aggressive, are believed to develop from intraepithelial carcinomas in the fallopian tube, and are genetically unstable with characteristic somatic TP53 mutations but rarely mutations characteristic of Type I tumors [7] .
Previous data also suggest that ovarian cancer pathogenesis may be dependent on the inflammatory response within the ovarian surface epithelium. This hypothesis is supported by an etiological hypothesis of ''incessant ovulation,'' which postulates that increased lifetime ovulations are associated with increased risk of ovarian cancer [10] . Ovulation causes repeated trauma to the ovarian surface epithelium that requires repair mediated by the inflammatory response through the recruitment of leukocytes, cytokines, and chemokines, release of nitrous oxide, DNA repair, and tissue restructuring [10] [11] [12] [13] [14] . This restructuring can result in epithelial cells trapped internally in inclusion cysts, where the local microenvironment appears to induce them to gain quasi-neoplastic characteristics such as increased p53 accumulation and a ninefold higher proliferation index than surface epithelial cells [15] .
Nuclear factor-kappaB (NF-jB) refers to a family of transcription factors (also called the Rel family) that regulate the expression of over 400 genes. These regulated genes are critical to numerous cellular processes and include a multitude of cytokines and chemokines, pro-inflammatory genes, adhesion molecules, acute phase response proteins, complement factors, stress response genes, oxidative enzymes, apoptosis genes, growth factors, and other transcription factors [16] [17] [18] . Due to this regulatory role, NF-jB has been implicated in several diseases including cardiovascular disease and various cancers [19, 20] . Evidence indicates that NF-jB is constitutively activated in many cancer cell lines, influencing cancer progression and response to chemotherapy [21, 22] . Therefore, we set out to review the hypothesis that NF-jB may play a role in ovarian cancer specifically and to identify the optimal approach for a large-scale study of inherited variation in this pathway and ovarian cancer risk.
A role for NF-jB in ovarian cancer
The NF-jB family of transcription factors has received much attention for its role in cancer since the discovery that c-rel is the human homologue of the avian retroviral oncogene v-rel [23] . Subsequent work has demonstrated roles for NF-jB-mediated signaling in promoting survival from pro-apoptotic stimuli, angiogenesis, proliferation, and inflammation-all characteristics of malignancy [24] . All of these NF-jB-influenced functions appear to play a role in ovarian cancer, underlying the importance of further understanding NF-kB-mediated events in order to better identify women at risk of developing ovarian cancer and to facilitate development of more effective therapeutic strategies.
NF-jB has been shown to be important directly in tumor cells. For example, the mitogen lysophosphatidic acid that is found in ascites fluid may induce proliferation by increasing levels of cyclin D1, an important cell cycle control protein [25] . LPA-induced increases in activity of a cyclin D1 promoter-driven reporter gene required the NF-jB site. Ovarian tumors can acquire enhanced NF-jB functions that allow them to circumvent apoptotic pathways and afford protection against environmental insults such as anti-tumor immune effectors or chemotherapy. Inhibition of NF-jB activity in vitro or in human cell line xenografts increases the sensitivity of the cells to apoptosis induced by both cisplatin [26] and paclitaxel [27] , drugs representing the platinum/taxane combination most commonly used as first-line treatment for ovarian cancer. Ovarian cancers are resistant to tumor necrosis factor alpha (TNFa)-induced apoptosis because tumor cells can upregulate pathways leading to the activation of NF-jB and induction of apoptosis inhibitory proteins [28] . In addition, using a dominant-negative IkBa construct to block NF-jB activity in the SKOV3 ovarian cancer cell line resulted in reduced expression of VEGF and IL-8, leading to reduced tumorigenicity, invasiveness, and angiogenesis in athymic mice [29] . Similar reductions were seen in cell line invasiveness, IL-8 production, and anchorage-independent growth after treatment with an IKKb inhibitor in experiments performed after determining that elevated IKKb levels and a 9-gene ''IKKb signature'' were associated with worse outcome in ovarian cancer patients [30] .
In addition to studies that assess all ovarian cancer cells as one population, cells phenotypically and functionally characterized as potential ovarian cancer stem cells have been shown to have constitutively activated NF-jB [31] . The group characterizing these cells further determined that expression of transcripts from the microRNA cluster miRNA199A2/214 are lower in the CD44-positive stem cell-like population than in CD44-negative, ''mature'' ovarian cancer cells, and that decreases in expression of this specific miRNA cluster are associated with decreased expression of Twist1, a transcription factor that controls IKKb levels [32] . Because Twist1 has an antagonistic function in NF-jB-mediated cytokine expression, it appears that the result of reduced expression of this miRNA cluster and decreased Twist 1 levels is increased NF-jB activity. Due to the strong potential for chemoresistant stem cells to contribute to ovarian cancer recurrence after initially effective chemotherapy, it is clear that understanding the potential role of NF-jB in driving stem cell activity is a critical area of study.
In addition to direct actions in tumor cells, NF-jBmediated events also contribute to the microenvironment and peritoneal inflammation associated with ovarian cancer. For example, activated thrombin, found in the inflammatory environment of the peritoneum in ovarian cancer patients, appears to induce monocytes to develop a tumor-associated macrophage phenotype. Monocytes treated with activated thrombin have elevated levels of activated NF-jB; supernatants from these cells increase ovarian cancer cell invasion in vitro. This increased invasiveness can be blocked with a neutralizing antibody targeting IL-8, an NF-jB-driven cytokine . The type of anti-tumor immune response that develops is controlled by chemokines and cytokines produced by infiltrating tumor macrophages, dendritic cells, and the tumors themselves to control the mobilization of the various T-cell subsets. For example, one mechanism by which ovarian cancer modulates immunity is through the production of interleukin-10 (IL-10). Synthesized directly by the tumor and infiltrating immune effectors, IL-10 blocks NF-jB activation in T-cells and dendritic cells and prevents activation of effective ovarian cancer anti-tumor immunity [40] [41] [42] .
Because of the vast body of evidence supporting the importance of NF-jB-regulated events to ovarian cancer cells and the anti-tumor immune response, we hypothesize that much of the unexplained risk of this inflammation-related cancer is due to genetic variations in the NF-jB pathway [43] .
Nuclear factor-kappaB subunits and primary signaling pathways NF-jB is present in cells in an uninduced state, requiring activation to initiate nuclear translocation and the ability to influence gene expression. It consists of five members, p50, p52, p65, Rel-B, and c-Rel [44] , that can form multiple homo-and hetero-dimers (p65/p50, p65/p65, p50/c-Rel, p50/p50, c-Rel/c-Rel, and p52/p52), the most common of which are p65/p50 and p52/Rel-B [45, 46] . The NF-jB dimers have specific non-redundant functions in various tissue and cell types [22, 46] . p50, p65, and p52 are found in most cell types and at the highest concentration in the thymus, whereas Rel-B and c-Rel are primarily found in lymphoid tissues [46] .
The primary NF-jB signaling pathway is referred to as the canonical pathway (Fig. 1) . Stimulation by TNFa and other ligands initiates a signaling cascade that assembles the IjB kinase (IKK) complex and promotes the degradation of the inhibitors of jB (IjB), resulting in the activation and nuclear translocation of NF-jB dimers [16] . The canonical pathway is particularly important for the ability of the myeloid (innate) cells of the immune system, including monocytes, macrophages, and dendritic cells, to communicate with the adaptive immune system [47] . NFjB is also important for the innate immune cells to sense ''danger'' through a family of molecules known as the tolllike receptors (TLRs) [48] .
Much less is understood about the non-canonical NFjB pathway. This signaling cascade involves ligation by CD40, B-cell activating factor (BAFF), and lymphotoxin beta (LTb), subsequent IKKa activation, and poly-ubiquitination and partial degradation of p100, which yields activated p52 and Rel-B dimers (Fig. 1) [45, 46, 49, 50] . In contrast to the canonical pathway, the non-canonical NF-jB receptor-mediated pathway is important for lymphoid organ development and the adaptive immune response [47] . Targeted disruptions in the individual NF-jB subunits can lead to abnormal splenic architecture. Due to the spleen's important role in both human and mouse immunity, it is likely that these splenic abnormalities play a role in some forms of immunodeficiency. NF-jB is also known to play key roles in the architecture of other immune organs such as the lymph nodes, which are important for the eradication of both infection and malignancy. One of the best-characterized roles of the non-canonical pathway is in the development of an adaptive immune response. For example, targeted disruption of IKKa expression blocks maturation of B-cells in the germinal centers of lymph nodes, indicating the important role of IKKa in the acquisition of humoral immunity [51] .
A role for polymorphisms
Inherited variation in key genes may account for some portion of ovarian cancer susceptibility. Familial aggregation of ovarian and breast cancer has long been established, and account for an estimated 5-10% of epithelial ovarian cancer cases [52, 53] . Highly penetrant mutations in BRCA1, BRCA2, and DNA mismatch repair genes explain less than 40% of familial epithelial ovarian cancer risk [54] ; however, approximately two-thirds of families with three or more cases of familial breast or ovarian cancer had BRCA1 or BRCA2 mutations [55, 56] . The remaining inherited risk is most likely due to combinations of common, less-penetrant alleles [57] [58] [59] [60] [61] . The most powerful method for identification of moderate risk alleles is a genetic association study examining frequencies of variants such as single-nucleotide polymorphisms (SNPs) in candidate genes of key biological pathways, which has been successful in identifying new risk alleles for a variety of cancers [62] [63] [64] , or via genome-wide association studies (GWAS). Thus far, variants in the 2q31, 3q25, 8q24, 9p22, 17q21, and 19p13 chromosomal regions [65] [66] [67] and in genes involved in cell cycle control [68] , steroid hormone metabolism [69] , DNA repair [70] , and one-carbon metabolism [71] have been associated with ovarian cancer susceptibility. Additional evidence is accumulating that inherited factors, including those in inflammation, relate to clinical outcome in ovarian cancer [72] [73] [74] [75] .
The identification of polymorphisms worthy of study in given genes can draw on putative-functional or location data (reviewed by Bhatti et al. [76] ) or can rely on informative tagSNPs selected on the basis of linkage disequilibrium (LD, the correlation of alleles along a chromosome). The structure of LD for common variants has been mapped by the International HapMap Project using genome-wide genotyping [77] , and the LD structure of both common and rarer variants is improved by the 1000 Genomes Project [78] using genome-wide sequencing. These projects allow investigators to harness the power of LD for common disease prediction [79] [80] [81] [82] [83] . Due to the strong LD within a region, only a few SNPs need to be assayed to successfully predict all of the common genetic variation once SNP correlations are estimated for a core of individuals. If LD structure within a particular gene is known, careful selection of a reduced set of SNPs that identify or ''tag'' a particular haplotype may provide as much information as genotyping all available SNPs [84] [85] [86] . These tagSNPs then theoretically represent all genetic variation exceeding a specified minor allele frequency (MAF). Thus, by genotyping the LD-selected subset of common variants, it is possible to perform a comprehensive analysis of all common variants in a candidate gene.
The purpose of the current investigation is to identify and classify the highest priority genes within the NF-jB signaling pathway, to evaluate publicly available LD data in the encoding genes, and to select a panel of SNPs representing genetic variation within these genes. The resulting set of annotated genes and variants is now available to the scientific community.
Methods

Classification of genes
Using the PubMed 1 search engine in December 2009, we identified genes involved in NF-jB signaling through a literature search including the phrases ''NF-kappaB,'' ''pathway,'' and ''gene.'' Genes were categorized into NFjB subpathways (canonical, non-canonical, or both canonical and non-canonical) and biological function within the subpathways. Biological function definitions were as follows: subunits (NF-jB proteins), activation (role in signaling cascade leading to NF-jB subunit activation), inhibition (inhibitory role), degradation (involved in proteasomal degradation), and nuclear function (nuclear proteins involved in transcription).
Evaluation of genotype data sources
We assessed three types of large-scale LD characterization projects: (1) 10 Pharmacogenetics and Risk of Cardiovascular Disease (PARC), 11 and Molecular Diversity and Epidemiology of Common Disease (MDECODE). 12 Based on European or European-American data availability for NF-jB genes, we identified, from among these sources, those sources which were appropriate for LD-based SNP selection and applied the tagSNP selection approach described below.
LD binning and choice of genotype data source Within each genotyped data source and for each gene, we binned SNPs with MAF C 0.05 that were pairwise correlated at r 2 C 0.9 using the algorithm implemented in ldSelect [87] . For genome-wide projects (the 1000 Genomes Project, the International HapMap Project, and Perlegen Sciences), gene regions were defined as 5 kb upstream and downstream using genomic coordinates based on RefSeq release 29 (NCBI build 36). For genes with data available in multiple LD sources, we then identified the ''best source'' of data as the source with the highest number of LD bins after tagSNP selection. It is conservative to include a greater number of tagSNPs rather than a smaller number of tagSNPs in the event that one source overestimated LD For example, even with an equal number of underlying SNPs, if Source A indicated a larger number of LD bins than Source B, we proceed with Source A's tagSNPs as analysis of data from Source A samples suggested lower LD within the gene and thus the need for more LD bins than Source B. More often, however, the source with the greatest number of LD bins was also the source with the greatest number of underlying SNPs, thus clearly capturing the greatest amount of genetic variation.
SNP selection
After LD binning using the best data source for each gene, we identified particular tagSNPs to assay within each bin. Using Illumina iSelect HD Custom Genotyping annotation (San Diego, CA), we prioritized tagSNPs first based on expected assay performance. One tagSNP was selected in bins with less than ten SNPs, two tagSNPs were selected in bins with 10-29 SNPs, and three tagSNPs were selected in bins with 30 or more SNPs. Within each gene, additional putative-functional SNPs with MAF C 0.05 (that were not tagSNPs) were also identified as non-synonymous, 5 0 UTR, 3 0 UTR, 1 kb 5 0 upstream, residing in a splice site (dbSNP version 129), or residing in an miRNA-binding site. 13, 14 Comparison to genome-wide panels
In order to assess the utility of creating a custom NF-jB SNP panel versus use of a commercially available platform, we compared our prioritized SNPs to: (1) SNPs available on the Illumina Infinium HD Human610-Quad BeadChip genome-wide SNP panel (San Diego, CA) that has been used in prior ovarian cancer GWAS [65] and (2) SNPs in the International HapMap Project Phase II which prior ovarian cancer GWAS have used as the basis for imputation of up to 2.5 million SNPs [65] . We estimated ''coverage'' of SNPs within NF-jB genes versus those available in two ways: (1) as the proportion of NF-jB LD bins with at least one tagSNP included on these panels and (2) as the proportion of NF-jB SNPs either tagged or directly assessed in bins included on these panels.
Results
Identification of the key components of NF-jB signaling
Our review identified 319 key genes in the NF-jB signaling pathway; these are classified in Table 1 by subpathway (canonical, non-canonical, or both) and biological function (subunits, activation, inhibition, degradation, and nuclear function). We excluded the 26S proteasome (degratory role) and RNA polymerase II (nuclear role) from consideration due to a lack of specificity to NF-jB signaling and an excessive number of genes encoding the many subunits required for the functional protein complexes. Supplemental Table 1 provides detailed information for each gene including protein descriptions, location, size, and references attesting to each gene's relevance in NF-jB signaling. The major components of the NF-jB signaling pathway are summarized below.
Activation of NF-jB subunits
Components of NF-jB signaling cascades include ligands, receptors, and intracellular target molecules that lead to IKK complex activation, IjB degradation, and activation of NF-jB dimers. The primary canonical NF-jB signaling pathway is initiated by binding of TNFa, a proinflammatory cytokine produced mainly by macrophages, but also by mast cells, lymphoid cells, endothelial cells, and fibroblasts (Fig. 2) [95] . NEMO is a non-enzymatic regulatory subunit that modulates and aids in IKKa and IKKb activation. In the non-canonical pathway, IKKa initiates processing of inhibitory p100 to functional p52 [46] . Activation of the IKK complex leads to processing of p100 and p105 and degradation of IjB, freeing NF-jB to enter the nucleus [46, 95] . For more details, see Fig. 2 for TNFa [88, [96] [97] [98] [99] [100] [101] [102] [103] and TCR ligand signaling pathways [18, [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] , Fig. 3 for IL-1 [88, [96] [97] [98] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] and LPS signaling pathways [18, 88, [126] [127] [128] [129] , and Fig. 4 for the non-canonical signaling pathway [50, 130, 131] .
Inhibition
Several molecules play inhibitory roles by seizing key molecules, preventing apoptosis, or interfering with proteasomal degradation (Table 1, Supplemental Table 1 ) [93] . The primary NF-jB inhibitors are the seven members of the IjB family, IjBa, IjBb, IjBe, IjBc, p100, p105, and BCL-3 [44] . The IKK complex phosphorylates IjBs at two serine residues, marking the inhibitors for poly-ubiquitination by the SCF b-TrCP complex and subsequent degradation by the 26S proteasome. Without ubiquitination and proteolysis of IjB, NF-jB complexes remain inactive in the cytoplasm [44, 46] . Preliminary evidence indicates that each IjB family member has a unique and specific role in the NF-jB pathway [132] [133] [134] [135] . IjBa, IjBb, IjBe, and 13 http://www.microrna.org/microrna/home.do. 14 http://www.targetscan.org/. AHR, AKT1, AKT2, ATM, AZI2, BCL10, BIRC3, BRCA1, CARD10,  CARD11, CARD14, CARD4, CARD9, CASP1, CASP2, CASP8,  CC2D1A, CD247, CD28, CD3D, CD3E, CD3G, CDC37, CDK4,  CFLAR, CRADD, CRP, CSNK2A2, CSNK2B, ECSIT, EGF, EGFR,  EIF2AK2, ERBB2, FADD, FRAP1, HRAS, HSP90AA1, HSP90AA2,  HSP90AB1, IKBKB, IKBKE, IKBKG, IL12A, IL15, IL17A, IL18, IL1A,   IL1B, IL1R1, IL1R2, IL2, IL6, IL8, IL1RAPL1, IL1RAPL2, ILK, IRAK1,  IRAK2, IRAK4, KRAS, LAT, LCK, LCP2, LBP, MALT1, MAP2K1,  MAP2K2, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7,  MAP3K1, MAP3K11, MAP3K2, MAP3K3, MAP3K7, MAP3K7IP1,  MAP3K7IP2, MAP3K7IP3, MAP3K8, MAP4K1, MAPK14, MAPK8,   MTDH, MYD88, NCAM1, NOD2, NRK, PDPK1, PELI1, PELI2,  PELI3, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PLCG1, PRKACA,  PRKACB, PRKCA, PRKCQ, PRKDC, PTPRC, RAF1, RHOA,  RIPK1, RIPK2, RIPK3, SPAG9, STAT1, SYK, TBK1, TBKBP1,  TICAM1, TICAM2, TIFA, TIRAP, TNF, TNFRSF10A, TNFRSF10B,  TNFRSF10D, TNFRSF1A, TNFSF10, TOLLIP, TP53, TRA@, TRADD,   TRAF2, TRAF7, TRB@, TRD@, TRG@, TRIP6, VISA, ZAP70   CD40, CD40LG, DYNLL1, LTA,  LTB, LTBR, MAP3K14,  TNFRSF11A, TNFRSF13B,  TNFRSF13C, TNFSF11  CHUK, FKBP5, IKBKAP, TANK, TLR1, TLR10, TLR2,  TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9,  TNFRSF1B, TRAF5, TRAF6, TRAPPC9, XIAP   -Inhibition  ARRB1, ARRB2, ATR, BAG4, BIRC2, CARD6, CARD8, CDKN2A,  CHEK1, CLU, CYLD, EGR1, ESR1, ESR2, G3BP2, HEXIM1,  HMOX1, IL10, IL1RN, IL3, IRAK3, ITGA3, MCC, MDM2, NALP12,  NFKBIA, NFKBIB, NFKBIE, NFKBIZ, NKIRAS1, NKIRAS2, NR1D1,  OTUD7B, PGR, PKN1, PPARA, PPARG, PPP1R13L, PPP6C, PTPN13,  PYCARD, RNF216, SOD1, TAL1, TNFAIP3, TNIP1, TNIP2, TNIP3,  TRAF1, KPNA2, KPNA6 ATF1, CREB1, CREBBP, EP300, FUS, GTF2A1, GTF2A2, GTF2B, GTF2E1, GTF2E2, GTF2F1, GTF2F2, GTF2H1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, HDAC1, HDAC3, HDAC6, JUN, KAT2B, MAPK1, MAPK3, MCM5, MCM7, POLR2A, POLR2B, POLR2C, POLR2D, POLR2E, POLR2F, POLR2G, POLR2H,POLR2I, POLR2 J, POLR2 K, POLR2L, RPS6KA3 , SP1, TAF1, TAF10, TAF11,  TAF12, TAF13, TAF15, TAF2, TAF3, TAF4, TAF4B, TAF5,  TAF6 , TAF7, TAF8, TAF9, TBP
Columns represent a NF-jB subpathway categorization (canonical, non-canonical, both, or unknown); rows represent the biological function of the gene (subunit, activation, inhibition, degradation, nuclear function, or unknown)
IjBc mask NF-jB's nuclear localization signal (NLS), which sequesters NF-jB in the cytoplasm, preventing nuclear translocation and transcription [132] . IjBa and IjBb have a similar binding affinity for NF-jB; however, IjBa also contains a nuclear export signal (NES) that enables IjBa to shuttle NF-jB complexes out of the nucleus. IjBb does not contain a NES, but is more effective than IjBa at masking NF-jB's NLS and preventing p65 and p50 translocation [46, [132] [133] [134] [135] . p100 and p105 are inhibitory precursors of p52 and p50, respectively, that are partially degraded, yielding functional p52 and p50. Although evidence is unclear, BCL-3 does not appear to have an inhibitory role, but instead may facilitate activation of p50 and p52 in the nucleus [44] .
Degradation
Proteolysis of inhibitory molecules is critical in regulating activation of the NF-jB signaling cascade [93] . The SCF
b-
TrCP complex marks the majority of inhibitors in the NF-jB pathway for degradation through poly-ubiquitination. The main components of this complex are beta-transducin repeat containing (b-TrCP) [136] [137] [138] , S-phase kinaseassociated protein 1 (Skp1), cullin 1 (Cul1), ring-box 1 (RBX1 or Roc1), and ubiquitin-conjugating enzyme E2D 1 (UBE2D1 or HbcH5; Table 1 , Supplemental Table 1 ) [139] . This complex recognizes phosphorylated inhibitors, and, through a series of events, it ubiquitinates these inhibitors, thus marking them for partial or complete degradation by the 26S proteasome [93] . Figure 5 provides more detail on the SCF b-TrCP complex partial degradation of p105/p100 and poly-ubiquitination of IjB [18, 93, [139] [140] [141] [142] [143] .
Nuclear function
After nuclear translocation, DNA-bound, transcriptionpromoting NF-jB complexes associate with the RNA polymerase II transcription machinery to initiate gene expression. RNA polymerase II can only initiate transcription after recruitment and assembly of the replication complex components. The general transcription factors, transcription factor for RNA polymerase II (TFII)-A, -B, -E, -F, and -H, contain either a TATA box region, a binding site for nuclear proteins, or an Inr element with a downstream promoter region that functions in a similar manner as the TATA box [93, 144, 145] . Other critical components for transcription of NF-jB-regulated genes include TATAbinding protein (TBP), 14 TBP-associated factors (TAFs) [93, 145] , K(lysine) acetyltransferase 2B (called PCAF) [146] , cAMP-responsive element-binding protein 1 (CREB) [147] , CREB-binding protein (CBP), and E1A-binding protein p300 (p300) [146, 148] . Figure 6 provides more detail on the components of the RNA polymerase II transcription complex [146] [147] [148] .
SNP selection
Evaluation of LD data sources
Among the LD sources listed in ''Methods'', we found that data from the following were optimal at the time of analysis ( 17 and Perlegen Sciences, 18 and the three gene resequencing programs SeattleSNPs, 19 NIEHS SNPs, 20 and Innate Immunity SNPs. 21 For 319 NF-jB identified candidate genes, 1000 Genomes Project data were available for all 302 autosomal genes (and none of the 17 chromosome X genes), International HapMap Project data were available for all but one gene (GTF2H2), and Perlegen Sciences data were available for 297 candidate genes; SeattleSNPs had resequenced 42 genes, Innate Immunity SNPs had resequenced 21 genes, and NIEHS SNPs had resequenced nine genes. Using data from each source, tagSNP selection was performed for all genes to bin SNPs with MAF C 0.05 and r 2 C 0.9. The 1000 Genomes Project was found to be the most informative source for 296 genes (92.8%), the International HapMap Project Phase II for 16 genes (5.0%, including 15 on chromosome X), Innate Immunity SNPs for three genes (0.9%, including one on chromosome X), SeattleSNPs for three genes (0.9%), and NIEHS SNPs for one gene (0.3%, including one on chromosome X); Perlegen Sciences data was not the most informative source for any gene. Supplemental Table 2 provides the most informative source identified for each gene.
TagSNPs and putative-functional SNPs
Summarizing across all genes and using the optimal LD source, 13,027 LD bins covering 36,181 common SNPs Fig. 4 Non-canonical activation pathways. Receptor binding of LTb, BAFF, CD40, and RANK initiate the non-canonical signaling pathway. TRAF proteins and other intracellular target molecules are recruited, eventually leading to the activation of NIK through an unknown mechanism. NIK contains binding domains that interact with TRAF2, TRAF3, TRAF5, and TRAF6, but the specific roles of TRAF and other proteins in the non-canonical pathway is still controversial. After NIK phosphorylation, IKKa phosphorylates p100, marking it for poly-ubiquitination and partial degradation by the SCF b-TrCP complex and 26S proteasome. Partial degradation of p100 yields functional p52, which most commonly forms heterodimers with Rel-B and translocates to the nucleus to initiate gene transcription b-TrCP complex, the adaptor proteins Skp1 and Cul1, and the RING protein Roc1 that recruits the E2 ubiquitinconjugating enzyme UbcH5. The precursor proteins p100 and p105 are partially degraded to yield functional p52 and p50, respectively. p105 contains a glucine-rich region (GRR), which separates the functional from inhibitory portions of the protein and is essential for its processing. After being marked for ubiquitination by the SCF b-TrCP complex, the proteasome degrades p105 and p100 until it hits the GRR region signaling the completion of processing and the functional subunit is released, or the proteasome is unable to properly unfold the GRR region, forcing it to complete processing prematurely and release p50/p65. Additionally, the SCF b-TrCP complex processes IjB after IKKb phosphorylates IjBa, IjBb, and IjBe. b-TrCP recognizes the degradation signal and UbcH5 and the SCF b-TrCP complex polyubiquitinate lysine residues on IjBa, which marks it for degradation by the 26S proteasome Table 2 provides detailed information about the number of bins within each gene as well as the number of SNPs tagged by tagSNPs. In total, a collection of 14,231 SNPs of interest to genotype in 319 NF-jB genes has been assembled representing common underlying genetic variation among populations of European descent. These SNPs do not attempt to cover rare variants (MAF \ 5%).
Coverage on genome-wide arrays
We evaluated coverage of our 13,027 identified NF-jB tagSNPs on the Illumina Infinium HD Human610-Quad BeadChip and in HapMap Phase II data (often used for imputation). Details per gene are provided in Supplemental Table 2 , and Fig. 7 summarizes coverage across genes. Generally, use of the Illumina 610-Quad without additional imputation would directly assess 22% of the identified NFjB bins and provide data on 50% of the total SNPs with MAF [ 0.05 in each gene. Thus, the NF-jB tagSNPs included on the Illumina 610-Quad tend to tag larger LD bins, reflecting a preference in Illumina's SNP selection for the most informative tagSNPs and placement of lower priority on singleton bins. The approach of dropping smaller bins is reasonable due to cost constraints, because smaller bins convey information on a minimal set of underlying SNPs. However, this coverage is not optimal for many applications. With additional imputation using HapMap Phase II data, coverage increases; on average, 43% of NF-jB bins would be assessed, providing data on 74% of the included SNPs. Again, larger bins have been identified by HapMap Phase II; however, the current availability of 1000 Genomes Project data indicates that less than optimal NF-jB coverage is provided by the use of HapMap Phase II imputation. We note that this is not due to the discovery of novel rare variants in 1000 Genomes Project data, as NF-jB LD binning was limited to SNPs with MAF [ 0.05. Coverage and statistical power is further reduced with use of HapMap Phase II imputation due to the use of imputation rather than directly genotyping SNPs of interest. To address these issues, GWAS panels are currently under commercial development, which are based on 1000 Genomes Project data, and these will fill a critical void in commercial arrays. In the interim, current ovarian cancer GWAS are not expected to have optimal inclusion of NF-jB tagSNPs. Custom SNP arrays based on the NF-jB variants identified here will provide maximal information about these key genes of interest to ovarian cancer and other phenotypes.
Discussion
NF-jB is a key regulator of expression of hundreds of genes involved in crucial cellular processes related to normal cellular function and carcinogenesis. Its signaling pathway involves a complex cascade of events initiated by immune and other signaling proteins, regulated by several inhibitory molecules, and that eventually leads to NF-jBmediated regulation of gene expression. There is an abundance of evidence linking a prolonged, aberrant inflammatory response with ovarian cancer. As the most lethal gynecologic malignancy, the quest for a better understanding of ovarian cancer genomics is critical. Due to NF-jB's vital role in responding to inflammatory signals, initiating expression of pro-inflammatory genes, and proven links between ovarian carcinogenesis and inflammation, a study examining variations in genes involved in the NF-jB pathway and ovarian cancer risk is warranted.
Here, we summarized the relevance of the NF-jB signaling pathway in ovarian cancer and identified 319 genes encoding critical components categorized by subpathway and biological function. Additionally, we identified 14,231 tagSNPs and putative-functional SNPs within each of these genes. Of LD data sources available in April 2010, we found that the data from the 1000 Genomes Project was more informative for the vast majority of genes than that from the International HapMap Project and other projects. We also found that coverage of variation in these genes on the commonly used [65] commercial panel Illumina Infinium HD Human610-Quad BeadChip was suboptimal, even considering imputation of missing genotypes using the International HapMap Project Phase II data. Thus, in order to comprehensively assess inherited variation in the NF-jB signaling pathway, a customized SNP panel, such as an Illumina iSelect HD Custom Genotyping, is preferable. As new versions of data from the 1000 Genomes Project are unveiled, it will be critical to re-evaluate genomic coverage of these candidate genes. The collection of SNPs we have currently identified is available to the scientific community studying association between variation in NF-jB signaling and any phenotype, including ovarian and other cancers [149] [150] [151] [152] as well as autoimmune [153] , vascular [154] , and muscular disorders [155] . 
